Corey Ventetuolo, MD
Pulmonary Disease · Riverside, RINPI 1538318241
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,545 of the $51,021 with a category attached, or 91.2%. 4 manufacturers reported payments, led by Merck at 50.6% of the total. Among pulmonary disease clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $809.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$26K
- Actelion Pharmaceuticals US, Inc.$12K
- Regeneron$9K
- United Therapeutics Corporation$5K
What the payments were for
- Consulting fees$46,54591%
- Travel & lodging$3,3727%
- Food & beverage$9612%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 25 | $25,839 |
| Actelion Pharmaceuticals US, Inc. | 13 | $11,707 |
| Regeneron | 9 | $8,688 |
| United Therapeutics Corporation | 16 | $4,787 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,021 in reported general payments places this provider in the 95th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ambrisentan | 12 | $72,663 |
| Dupixent SyringeDupilumab | 11 | $39,156 |
| EliquisApixaban | 12 | $6,795 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,015 |
| Tadalafil | 36 | $4,733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $494 |
| Furosemide | 45 | $278 |
| Potassium Chloride | 11 | $234 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Riverside
- John LadettoRiverside$39K
- Douglas MartinRiverside$4K
- James KlingerRiverside$3K
- Matthew BallenbergerRiverside$1K
- Peter KarczmarRiverside$245
- Ronald GilmanRiverside$136
- James MyersRiverside$136
- Seema AminRiverside$110
- Michael BlundinRiverside$100
- E Jane CarterRiverside$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.